Skip to main content
Premium Trial:

Request an Annual Quote

Pharmacogenomics Firm Genetika+ Raises $10M in Series A Round

NEW YORK — Israeli pharmacogenomics firm Genetika+ said on Thursday that it has raised $10 million in a Series A financing round.

The round was led by GreyBird Ventures with participation from Meron Capital, Jumpspeed Ventures, Sapir Venture Partners, and individual investors Howard Morgan and Michael Zeisser.

Genetika+ is developing a test that uses blood-based neurological biomarkers and a patient's genetic and medical history to predict the best antidepressant drug or drug combination for that individual. The company also offers a service to help depression drug developers predict drug responses in patient groups.

Genetika+ said it will use the Series A funding to expand clinical trials of its technology, increase its manufacturing capabilities, and establish a clinical lab in Boston, as well as add employees in Israel and the US.

"Millions of patients around the world face an arduous journey to find the most effective medication to treat their depression," Genetika+ cofounder and CEO Talia Cohen Solal said in a statement. "We're excited to secure this funding, which will enable the first biologically relevant measures to inform potentially life-changing medication selection decisions."

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.